US 12,264,201 B2
Bispecific antibody targeting IL-1R1 and NLPR3
Victoria McGilligan, Londonderry (GB)
Assigned to UNIVERSITY OF ULSTER, Coleraine (GB)
Appl. No. 17/275,986
Filed by University of Ulster, Coleraine (GB)
PCT Filed Sep. 16, 2019, PCT No. PCT/EP2019/074745
§ 371(c)(1), (2) Date Mar. 12, 2021,
PCT Pub. No. WO2020/053447, PCT Pub. Date Mar. 19, 2020.
Claims priority of application No. 1815045 (GB), filed on Sep. 14, 2018.
Prior Publication US 2022/0033507 A1, Feb. 3, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61P 27/06 (2006.01); A61P 29/00 (2006.01)
CPC C07K 16/2866 (2013.01) [A61P 27/06 (2018.01); A61P 29/00 (2018.01); C07K 16/28 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/34 (2013.01); C07K 2317/622 (2013.01); C07K 2317/77 (2013.01)] 13 Claims
 
1. An NLRP3 inflammasome modulator that binds to IL-1R1 and NLRP3;
wherein the NLRP3 inflammasome modulator comprises a bispecific antibody having a first antibody moiety and a second antibody moiety,
the first antibody moiety comprising three heavy chain complementary determining regions (CDRs) and three light chain CDRs, wherein the heavy chain CDRs of the first antibody moiety comprise GYPFTTAG (SEQ ID NO: 60), MNTOSEVP (SEQ ID NO: 61), and AKSVYFNWRYFDV (SEQ ID NO: 62), wherein the light chain CDRs of the first antibody A moiety comprise QSISDY (SEQ ID NO: 63), YAS, and QHGHSFPLT (SEQ ID NO: 64); and
the second antibody moiety comprising three heavy chain complementary determining regions (CDRs) and three light chain CDRs, wherein the heavy chain CDRs of the second antibody moiety comprise GFTFSDYY (SEQ ID NO: 65), ISDGGTYT (SEQ ID NO: 66), and ARGWVSTMVKLLSSFPY (SEQ ID NO: 67), wherein the light chain CDRs of the second antibody moiety comprise TGAVTTSNY (SEQ ID NO: 68), GTN, and ALWYSNYWV (SEQ ID NO: 69).